Qin Xian, Zhu Li, Zhong Yuan, Wang Yi, Luo Xiaoshan, Li Jiawei, Yan Fei, Wu Guicheng, Qiu Juhui, Wang Guixue, Qu Kai, Zhang Kun, Wu Wei
Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University Chongqing 400030 China
Chongqing University Three Gorges Hospital, Chongqing Municipality Clinical Research Center for Endocrine and Metabolic Diseases Chongqing 404000 China.
Chem Sci. 2024 Apr 5;15(20):7524-7544. doi: 10.1039/d4sc00761a. eCollection 2024 May 22.
A right-side-out orientated self-assembly of cell membrane-camouflaged nanotherapeutics is crucial for ensuring their biological functionality inherited from the source cells. In this study, a universal and spontaneous right-side-out coupling-driven ROS-responsive nanotherapeutic approach, based on the intrinsic affinity between phosphatidylserine (PS) on the inner leaflet and PS-targeted peptide modified nanoparticles, has been developed to target foam cells in atherosclerotic plaques. Considering the increased osteopontin (OPN) secretion from foam cells in plaques, a bioengineered cell membrane (OEM) with an overexpression of integrin α9β1 is integrated with ROS-cleavable prodrugs, OEM-coated ETBNPs (OEM-ETBNPs), to enhance targeted drug delivery and on-demand drug release in the local lesion of atherosclerosis. Both and experimental results confirm that OEM-ETBNPs are able to inhibit cellular lipid uptake and simultaneously promote intracellular lipid efflux, regulating the positive cellular phenotypic conversion. This finding offers a versatile platform for the biomedical applications of universal cell membrane camouflaging biomimetic nanotechnology.
ACS Appl Mater Interfaces. 2024-9-4
Regen Biomater. 2021-7-18
ACS Appl Mater Interfaces. 2021-8-4
ACS Appl Mater Interfaces. 2023-10-11
J Nanobiotechnology. 2025-4-7
J Cell Biol. 2022-9-5
Int J Biol Sci. 2022